Authors

Dr. Abramson is Professor of Medicine at Harvard Medical School and Director of the Center for Lymphoma at the Mass General Cancer Center.

Latest:

Dr Abramson on Findings with Glofitamab, Gemcitabine and Oxaliplatin in R/R DLBCL

Jeremy Abramson, MD, discusses the use of glofitamab with gemcitabine and oxaliplatin in patients with relapsed/refractory DLBCL.

Jeremy Segal, MD, PhD

Latest:

Dr. Segal on Next-Generation Sequencing for Lung Cancer

Jeremy Segal, MD, PhD, discusses the use of next-generation sequencing for patients with lung cancer.

Jeremy Slade Abramson, MD

Latest:

Dr. Abramson Discusses TRANSCEND in Relapsed/Refractory B-Cell Lymphomas

Jeremy Slade Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the updated results of the TRANSCEND study in patients with relapsed/refractory b-cell lymphomas.

Jeri L. Ashley, RN, Baptist Memorial

Jerome G. Kim, MD

Latest:

Dr. Jerome Kim on Geriatric Assessment Tool for Older Patients With Cancer

Jerome G. Kim, MD, medical oncologist, hematologist, Kaiser Permanente, discusses the feasibility of an assessment tool for older adults with cancer using web-based platforms.

Jerome Galon, PhD

Latest:

Next Steps for Immunoscore in Oncology

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.

Jerry Conway

Latest:

The Role of Companion Diagnostic Testing in Payer Decision Making

Companion diagnostics can enable significant improvements in safety, efficacy, outcomes, and cost-effectiveness associated with many existing and new therapies.

Jerry Lanchbury, PhD

Latest:

Jerry Lanchbury, PhD, Describes Myriad's HRD Test

Jerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) test.

Jerry W. Mitchell, MD

Latest:

Dr. Mitchell on Clinical Trials Exploring Medical Marijuana for Patients With Cancer

Jerry W. Mitchell, MD, oncologist, Zangmeister Cancer Center, discusses clinical trials exploring medical marijuana for patients with cancer.

Jesper Andersen, PhD

Latest:

Challenges Facing the Future of Cholangiocarcinoma

Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the challenges facing the future treatment of patients with cholangiocarcinoma.

Jessica Bauman, MD

Latest:

Dr. Bauman on Treatments for Patients With BRAF-Mutant NSCLC

Jessica Bauman, MD, assistant professor, Department of Hematology/Oncology, associate program director, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, discusses treatments for patients with BRAF-mutant non–small cell lung cancer (NSCLC).

Jessica Bauman, MD, Fox Chase Cancer Center

Latest:

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing

The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care.

Jessica Blackburn, PhD

Latest:

Zebrafish Are Making Waves as Cancer Models

The field of cancer biology is entering a postgenomic era in which most types of human cancer will have been extensively sequenced through efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium.

Jessica C. Gooch, MD

Latest:

Navigating the Job Search for Surgical Oncology Fellows

As the end of training approaches, the job hunt begins. Below are some tips to follow to make the job-hunting process easier.

Jessica DeMartino, PhD

Latest:

Impact of Risk Evaluation and Mitigation Strategies in Oncology

The management of risk in medicine is emerging as a priority topic for numerous stakeholders, including patients, providers (physicians, other prescribers, and pharmacists), specialty pharmacies, industry, and government organizations.

Jessica Donington, MD, MSCR

Jessica Donington, MD, MSCR, is a professor of surgery and chief of the Section of Thoracic Surgery at University of Chicago Medicine in Illinois.

Latest:

Unmet Needs Research Aims to Address in Early-Stage NSCLC

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss ongoing research in early-stage non–small cell lung cancer.

Jessica Frakes, MD

Latest:

Dr. Frakes on Late Toxicities in HPV-Associated Oropharynx Squamous Cell Carcinoma

Jessica Frakes, MD, assistant member, Department of Radiation Oncology, Moffitt Cancer Center, discusses some of the late toxicities seen in patients with HPV-positive oropharynx squamous cell carcinoma.

Jessica Geiger, MD

Latest:

Dr. Geiger on Challenges of Patients With CSCC Enrolled in KEYNOTE-630 Trial

Jessica Geiger, MD, medical oncologist, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses challenges with the patient population enrolled in the phase III KEYNOTE-630 trial exploring the use of adjuvant pembrolizumab (Keytruda) in cutaneous squamous cell carcinoma.

Jessica Hergert

Assistant Editor,

Latest:

Embracing the Challenge and the Grind: Paul G. Richardson is a Giant of Cancer Care in Myeloma

Paul G. Richardson, MD, started his journey in medicine delivering tea and biscuits to patients and ended up making seminal advances in myeloma care.

Jessica K. Altman, MD

Latest:

Dr. Altman on Gilteritinib in Patients With Relapsed/Refractory AML

Jessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in FLT3-mutation–positive patients with acute myeloid leukemia (AML).